5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

 

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
Avatar

Case Study Presentation on Treatment Approach for mUC: What Are the Preferred 2L and 3L NCCN Guidelines Recommendations?

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Heather Greene
By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Heather Greene
233 views
March 13, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

19:39
Pfizer Hematology

Making the First Chance Count: Manuel

Feat. A. Ip

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss
Genitourinary Cancers
23:02

Current Landscape of Molecular Testing in Prostate Cancer: Which Tes…

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

D. Vaena

582 views
07:04

Non-Muscle Invasive Bladder Cancer, Pembro Approval and New agents O…

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

B. Somer

187 views
14:55

Management of Metastatic Urothelial Cancer: Prognostic Value of ctDN…

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

B. Somer

148 views
08:49

Case Study Presentation on Treatment Approach for mUC: What Are the …

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

H. Greene

233 views
09:31

Erdafitinib Treatment of 77 y/o Female With Metastatic Urothelial Ca…

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

H. Greene

136 views